One target, different effects: A comparison of distinct therapeutic antibodies against the same targets

Pharmacology, Toxicology and Pharmaceutical Science

• Tumor Necrosis Factor 100%
• Epidermal Growth Factor Receptor 100%
• Vasculotropin 66%
• Monoclonal Antibody 66%
• Therapeutic Use 33%
• Malignant Neoplasm 33%
• Disease 33%
• Infliximab 33%
• Golimumab 33%
• Certolizumab Pegol 33%
• Adalimumab 33%

Immunology and Microbiology

• Therapeutic Antibodies 100%
• Immunology 100%
• Tumor Necrosis Factor 60%
• CD20 60%
• Monoclonal Antibody 40%
• Vasculotropin 40%
• Preclinical Study 20%
• Infliximab 20%
• Adalimumab 20%
• Certolizumab Pegol 20%
• Golimumab 20%
• Immune System Disorders 20%